TY - JOUR
T1 - Endothelium- and smooth muscle-dependent vasodilator effects of Citrus aurantium L. var. amara
T2 - Focus on Ca2+ modulation
AU - Kang, Purum
AU - Ryu, Kang Hyun
AU - Lee, Jeong Min
AU - Kim, Hyo Keun
AU - Seol, Geun Hee
N1 - Funding Information:
This work was supported by a grant from National Research Foundation of Korea (NRF) funded by the Korean government (MSIP) (No. 2012R1A2A2A02007145 ).
Publisher Copyright:
© 2016 Elsevier Masson SAS.
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Neroli, the essential oil of Citrus aurantium L. var. amara, is a well-characterized alleviative agent used to treat cardiovascular symptoms. However, because it has been found to have multiple effects, its mechanism of action requires further exploration. We sought to clarify the mechanism underlying the actions of neroli in mouse aorta. In aortic rings from mice precontracted with prostaglandin F2 alpha, neroli induced vasodilation. However, relaxation effect of neroli was decreased in endothelium-denuded ring or pre-incubation with the nitric oxide synthase inhibitor NG-Nitro-l-arginine-methyl ester (L-NAME). And also, neroli-induced relaxation was also partially reversed by 1H-[1,2,4] oxadiazolo [4,3-a] quinoxalin-1-one (ODQ), a soluble guanylyl cyclase (sGC) inhibitor. In addition, neroli inhibited extracellular Ca2+-dependent, depolarization-induced contraction, an effect that was concentration dependent. Pretreatment with the non-selective cation channel blocker, Ni2+, attenuated neroli-induced relaxation, whereas the K+ channel blocker, tetraethylammonium chloride, had no effect. In the presence of verapamil, added to prevent Ca2+ influx via smooth muscle voltage-gated Ca2+ channels, neroli-induced relaxation was reduced by the ryanodine receptor (RyR) inhibitor ruthenium red. Our findings further indicate that the endothelial component of neroli-induced vasodilation is partly mediated by the NO-sGC pathway, whereas the smooth muscle component involves modulation of intracellular Ca2+ concentration through inhibition of cation channel-mediated extracellular Ca2+ influx and store-operated Ca2+ release mediated by the RyR signaling pathway.
AB - Neroli, the essential oil of Citrus aurantium L. var. amara, is a well-characterized alleviative agent used to treat cardiovascular symptoms. However, because it has been found to have multiple effects, its mechanism of action requires further exploration. We sought to clarify the mechanism underlying the actions of neroli in mouse aorta. In aortic rings from mice precontracted with prostaglandin F2 alpha, neroli induced vasodilation. However, relaxation effect of neroli was decreased in endothelium-denuded ring or pre-incubation with the nitric oxide synthase inhibitor NG-Nitro-l-arginine-methyl ester (L-NAME). And also, neroli-induced relaxation was also partially reversed by 1H-[1,2,4] oxadiazolo [4,3-a] quinoxalin-1-one (ODQ), a soluble guanylyl cyclase (sGC) inhibitor. In addition, neroli inhibited extracellular Ca2+-dependent, depolarization-induced contraction, an effect that was concentration dependent. Pretreatment with the non-selective cation channel blocker, Ni2+, attenuated neroli-induced relaxation, whereas the K+ channel blocker, tetraethylammonium chloride, had no effect. In the presence of verapamil, added to prevent Ca2+ influx via smooth muscle voltage-gated Ca2+ channels, neroli-induced relaxation was reduced by the ryanodine receptor (RyR) inhibitor ruthenium red. Our findings further indicate that the endothelial component of neroli-induced vasodilation is partly mediated by the NO-sGC pathway, whereas the smooth muscle component involves modulation of intracellular Ca2+ concentration through inhibition of cation channel-mediated extracellular Ca2+ influx and store-operated Ca2+ release mediated by the RyR signaling pathway.
KW - Citrus aurantium L. var. amara
KW - Endothelium
KW - Vascular smooth muscle
KW - Vasodilation
UR - http://www.scopus.com/inward/record.url?scp=84973548727&partnerID=8YFLogxK
U2 - 10.1016/j.biopha.2016.05.030
DO - 10.1016/j.biopha.2016.05.030
M3 - Article
C2 - 27470386
AN - SCOPUS:84973548727
SN - 0753-3322
VL - 82
SP - 467
EP - 471
JO - Biomedicine and Pharmacotherapy
JF - Biomedicine and Pharmacotherapy
ER -